JAGX
Jaguar HealthFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The January 2026 Future Pak transaction brought meaningful non-dilutive capital, reduced operating complexity, and lets Jaguar focus on rare-disease crofelemer programs; if Q2 2026 MVID data are supportive, the equity could rerate sharply from a distressed base [#PR-2026-01-12][#PR-2026-01-22].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Going-concern risk remains explicit in the 2026 10-K despite the January licensing cash infusion.
Momentum
68
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.38 · Bull $0.90 · Bear $0.12
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-05-29 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $7.50
Why
Momentum68 · Δ7d -
Value41 · Δ7d +0.1
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
68
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
0
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 68.0 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-05-29
Fundamentals (TTM)
As of 2026-05-29
Market Cap
$2.14M
Beta
0.10
Shares Out
4.54M
P/E (TTM) · Derived
-0.1
P/S (TTM)
0.40
P/FCF (TTM) · Derived
-0.02
Rev YoY
-0.8%
EPS YoY
+76.1%
Gross Margin
+81.9%
Op Margin
-294.0%
Net Debt
$27.54M
Current Ratio
0.81
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology